CENTRAL FAX CENTER

NOV 0 4 2004 PTO/SB/21 (09-04)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Personwork Reduction Act of 1995, no persons are regulated to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/616,959 Filing Date TRANSMITTAL July 11, 2003 First Named Inventor **FORM** Elisabeth DEFOSSA et al. Art Unit Examiner Name Davis, Zinna Northington (to be used for all correspondence after initial filing) Attorney Docket Number DEAV2002/0048 US NP Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(\$) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(\$) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Discipliner **Edension of Time Request** below): Response to Restriction Request for Refund Express Abandonment Request CD. Number of CD(s) Information Disclosure Statement Landscape Table on CD Remarks Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature Printed name Barbara E. Kurys Reg. No. Date 34,650 November 04, 2004 CERTIFICATE OF TRANSMISSION/MAILING I heraby certify that this correspondence is being facsimite transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 ; Total No. of Pages Transmitted: Signature

This collection of Information is required by 37 CFR 1.5. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer. U.S. Patent and Trademerk Office. U.S. Department of Commerce, P.O. Box 1450. Accounting VA 22313-1450, OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

November 04, 2004

Generia Walker

Typed or printed name

,

CENTRAL FAX CENTER

NO. 9452 P. 2

NOV 0 4 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

Davis, Zinna Northington

Elisabeth DeFossa et al

Art Unit:

1625

Application No.: 10/616,959

Filed:

July 11, 2003

TELEFAX CERTIFICATE

Title:

UREA-AND URENTHANE-SUBSTITUTED ACYLUREAS.

PROCESS FOR THEIR

PREPARATION AND THEIR USE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for

Response To Restriction Requirement

Mail Stop Art Unit 1625 Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

This paper is filed in response to the Office Action of June 4, 2004.

In response to the Restriction Requirement imposed by the Examiner in the above-referenced Office Action, Applicant hereby provisionally elects Group I. Applicant hereby provisionally elects the species that is Example 13 in Table 1 on page 29 of the specification.

The Examiner has requested that Applicant list all claims readable on the species election. Claims that read on the species include claims 1-7.

The Commissioner is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication to our Deposit Account No.18-1982. If a fee is required for an extension of time under 37 C.F.R. Section 1.136 not accounted for above, such extension is requested and should also be charged to our Deposit Account.

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-2965 Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0048 US NP